Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience
Cancer Letters · 2023-04 · 559 · 216119
DOI: 10.1016/j.canlet.2023.216119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-04. Verfasst von Jaewang Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; Department of Biome…. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 162 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
Cancer metabolic alterations have been emphasized to protect cancer cells from cell death. The metabolic reprogramming toward a mesenchymal state makes cancer cells resistant to therapy but vulnerable to ferroptosis induction. Ferroptosis is a new form of regulated cell death based on the iron-dependent accumulation of excessive lipid peroxidation. Glutathione peroxidase 4 (GPX4) is the core regulator of ferroptosis by detoxifying cellular lipid peroxidation using glutathione as a cofactor. GPX4 synthesis requires selenium incorporation into the selenoprotein through isopentenylation and selenocysteine tRNA maturation. GPX4 synthesis and expression can be regulated by multiple levels of its transcription, translation, posttranslational modifications, and epigenetic modifications. Targeting GPX4 in cancer may be a promising strategy for effectively inducing ferroptosis and killing therapy-resistant cancer. Several pharmacological therapeutics targeting GPX4 have been developed constantly to activate ferroptosis induction in cancer. The potential therapeutic index of GPX4 inhibitors remains to be tested with thorough examinations of their safety and adverse effects in vivo and clinical trials. Many papers have been published continuously in recent years, requiring state-of-the-art updates in targeting GPX4 in cancer. Herein, we summarize targeting the GPX4 pathway in human cancer, which leads to implications of ferroptosis induction for tackling cancer resilience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; Department of Biomedical Science, General Graduate School, CHA University, Seongnam, Repu…
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Lee, J., & Roh, J. L. (2023). Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience. Cancer Letters, 559, 216119. https://doi.org/10.1016/j.canlet.2023.216119
Vancouver
Lee J, Roh JL. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience. Cancer Letters. 2023;559:216119. doi:10.1016/j.canlet.2023.216119
BibTeX
@article{Lee2023,
author = {Lee, Jaewang and Roh, Jong-Lyel},
title = {Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience},
journal = {Cancer Letters},
year = {2023},
volume = {559},
pages = {216119},
doi = {10.1016/j.canlet.2023.216119}
}
EUVIMED